Prelude Therapeutics

PRLD

Market cap $323M

PRLD Hedge Fund Activity: Q1 2026 in Review

55 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q1 2026, worth a combined $105M — up 27% from $82.6M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new PRLD positions and 5 closed out — a net gain of 8 holders — while 20 added to existing stakes and 11 trimmed.

The largest buyer was EcoR1 Capital, opening a new position worth an estimated $2.48M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $2.19M sold.

• 55 institutional investors held Prelude Therapeutics (PRLD) as of Q1 2026, up from 48 in Q4 2025.
• Funds reported $105M of Prelude Therapeutics stock for Q1 2026, up 27% quarter-over-quarter.
• 13 funds opened new Prelude Therapeutics positions in Q1 2026 and 5 closed out, a net change of +8 holders.
• The largest Prelude Therapeutics buyer in Q1 2026 was EcoR1 Capital, an estimated $2.48M added.
• The largest Prelude Therapeutics seller in Q1 2026 was T. Rowe Price Associates, an estimated $2.19M sold.

Based on aggregated 13F filings for Q1 2026.